These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 20665382)

  • 1. Chronic hepatitis C of 28 years' duration characterized by early development of stage 2 (of 4) fibrosis but no significant progression over the subsequent 18 years.
    Verna EC; Lefkowitch JH; Berk PD
    Semin Liver Dis; 2010 Aug; 30(3):302-9. PubMed ID: 20665382
    [No Abstract]   [Full Text] [Related]  

  • 2. Natural history of hepatic fibrosis progression in chronic hepatitis C virus infection in India.
    Hissar SS; Kumar M; Tyagi P; Goyal A; Suneetha PV; Agarwal S; Rastogi A; Sakhuja P; Sarin SK
    J Gastroenterol Hepatol; 2009 Apr; 24(4):581-7. PubMed ID: 19032460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of HCV treatment: who does well and who does not?
    Hsu CS; Kao JH
    J Gastroenterol Hepatol; 2010 May; 25(5):846-8. PubMed ID: 20546434
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term monitoring of platelet count, as a non-invasive marker of hepatic fibrosis progression and/or regression in patients with chronic hepatitis C after interferon therapy.
    Taniguchi H; Iwasaki Y; Fujiwara A; Sakaguchi K; Moriya A; Yu PC; Takaki A; Fujioka S; Shimomura H; Shiratori Y
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):281-7. PubMed ID: 16460487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies.
    Poynard T; Ngo Y; Munteanu M; Thabut D; Massard J; Moussalli J; Varaud A; Benhamou Y; Ratziu V
    Antivir Ther; 2010; 15(4):617-31. PubMed ID: 20587855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients.
    Patton HM; Patel K; Behling C; Bylund D; Blatt LM; Vallée M; Heaton S; Conrad A; Pockros PJ; McHutchison JG
    J Hepatol; 2004 Mar; 40(3):484-90. PubMed ID: 15123364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting progressive hepatic fibrosis stage on subsequent liver biopsy in chronic hepatitis C virus infection.
    Collier JD; Woodall T; Wight DG; Shore S; Gimson AE; Alexander GJ
    J Viral Hepat; 2005 Jan; 12(1):74-80. PubMed ID: 15655051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis.
    Petit JM; Benichou M; Duvillard L; Jooste V; Bour JB; Minello A; Verges B; Brun JM; Gambert P; Hillon P
    Am J Gastroenterol; 2003 May; 98(5):1150-4. PubMed ID: 12809841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver biopsy and noninvasive alternatives in relationship to the duration of antiviral treatment for hepatitis C.
    Colletta C; Smirne C; Marini C; Pirisi M
    J Clin Gastroenterol; 2008 Feb; 42(2):219-20. PubMed ID: 18209600
    [No Abstract]   [Full Text] [Related]  

  • 10. The APRI and the RVR.
    Snyder N; Petersen JR
    J Clin Gastroenterol; 2009; 43(5):500-1. PubMed ID: 19098684
    [No Abstract]   [Full Text] [Related]  

  • 11. The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis.
    Sanyal AJ; Fontana RJ; Di Bisceglie AM; Everhart JE; Doherty MC; Everson GT; Donovan JA; Malet PF; Mehta S; Sheikh MY; Reid AE; Ghany MG; Gretch DR; Halt-C Trial Group
    Gastrointest Endosc; 2006 Dec; 64(6):855-64. PubMed ID: 17140886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis.
    Roche B; Sebagh M; Canfora ML; Antonini T; Roque-Afonso AM; Delvart V; Saliba F; Duclos-Vallee JC; Castaing D; Samuel D
    Liver Transpl; 2008 Dec; 14(12):1766-77. PubMed ID: 19025933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the treatment of hepatitis C.
    Lawrence SP
    Adv Intern Med; 2000; 45():65-105. PubMed ID: 10635046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chronic hepatitis C: etiology, pathogenesis, treatment].
    Maev IV; Polunina TE; Polunina EV
    Klin Med (Mosk); 2009; 87(11):12-7. PubMed ID: 20143559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression of fibrosis in chronic hepatitis C.
    Ghany MG; Kleiner DE; Alter H; Doo E; Khokar F; Promrat K; Herion D; Park Y; Liang TJ; Hoofnagle JH
    Gastroenterology; 2003 Jan; 124(1):97-104. PubMed ID: 12512034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic fibrogenesis and hepatitis C.
    Rockey DC
    Semin Gastrointest Dis; 2000 Apr; 11(2):69-83. PubMed ID: 10803632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: predicting response in hepatitis C virus therapy.
    Mihm U; Herrmann E; Sarrazin C; Zeuzem S
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1043-54. PubMed ID: 16611264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The natural history of hepatitis C cirrhosis after liver transplantation.
    Firpi RJ; Clark V; Soldevila-Pico C; Morelli G; Cabrera R; Levy C; Machicao VI; Chaoru C; Nelson DR
    Liver Transpl; 2009 Sep; 15(9):1063-71. PubMed ID: 19718647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should trichrome stain be used on all post-liver transplant biopsies with hepatitis C virus infection to estimate the fibrosis score?
    Tretheway D; Jain A; LaPoint R; Sharma R; Orloff M; Milot P; Bozorgzadeh A; Ryan C
    Liver Transpl; 2008 May; 14(5):695-700. PubMed ID: 18324621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histological response to interferon alfa-based therapies in hepatitis C.
    Lee SS
    Semin Liver Dis; 2004; 24 Suppl 2():55-60. PubMed ID: 15346247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.